13.53USD-1.08%Mkt Cap: 1.18B USDP/E: —Last update: 2026-05-26
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap1.18B USD
Enterprise Value726.71M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-162.45M USD
Revenue/Share—
Last Price13.53 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees137
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.05
PEG—
EV/EBITDA-3.80
EV/Revenue—
P/S—
P/B2.39
EPS (TTM)-2.03
EPS (Forward)-2.33
52W Range
3.89030% of range36.26
52W High36.26 USD
52W Low3.890 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-33.95%
ROA-30.45%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-146.72M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-6.68%
Net Debt-501.39M USD
Net Debt/EBITDA2.62
Balance Sheet
Debt/Equity0.01
Current Ratio10.88
Quick Ratio10.79
Book Value/Sh5.881 USD
Cash/Share5.785 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)41.82 USD
Target Range23.00 USD – 62.00 USD
# Analysts11
Ownership
Shares Out.87.35M
Float59.37M
Insiders1.80%
Institutions119.37%
Short Interest
Short Ratio14.9d
Short % Float18.14%
Short % Out.14.93%
Shares Short13.04M
Short (prev mo.)12.27M
Technical
SMA 5014.91 (-9.2%)
SMA 20016.52 (-18.1%)
Beta2.06
S&P 52W Chg28.31%
Avg Vol (30d)974.16K
Avg Vol (10d)1.27M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—